Skip to main content
TipRanks
Go Ultimate75% OFF

Context Therapeutics (CNTX) AI Stock Analysis

332 Followers
CNTX

Context Therapeutics

(NASDAQ:CNTX)

Select Model
Rating:45Neutral
Price Target:$0.19â–²(16.27% Upside)
Action:reiterated
Date:11/13/26

Overall score is held down primarily by weak financial performance (no revenue, rising losses, and ongoing cash burn) and bearish technicals (below key moving averages with negative MACD). A positive corporate update on early clinical data and trial progress provides some support, but it is not enough to offset the financial and trend headwinds.

Positive Factors
Low LeverageVery low leverage limits interest and refinancing pressure, preserving financial flexibility while the company advances its pipeline. This conservative financing profile gives management more room to allocate capital toward clinical development and reduces the balance-sheet risk that often compounds losses at early-stage biotechs.
Negative Factors
No Commercial RevenueThe absence of product revenue means CNTX has no demonstrated commercial engine to fund operations or validate market demand. Until a candidate is successfully developed and commercialized, the business remains dependent on clinical progress and external capital, making financial performance highly sensitive to development outcomes.

Context Therapeutics (CNTX) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%200%250%CNTX-84.77%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$15.29M
Dividend Yield
―
Average Volume (3M)
1.45M
Price to Earnings (P/E)
-0.4
Beta (1Y)
0.89
Revenue Growth
―
EPS Growth
-66.49%
Country
US
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Context Therapeutics Business Overview & Revenue Model

Company Description

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated...

How the Company Makes Money

As a clinical-stage biotechnology company, Context Therapeutics does not have a broadly disclosed, product-based commercial revenue model in publicly available information; therefore, specific recurring revenue streams from product sales are null. Th...

Context Therapeutics Financial Statement Overview

Summary

Financial profile remains weak: no revenue, widening net losses (TTM about -$43.9M), and persistent negative operating/free cash flow (TTM about -$34.0M) imply ongoing funding needs. The key offset is very low leverage (debt-to-equity near zero), but equity has been shrinking, reflecting cumulative losses and burn.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

27Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-43.83M-36.11M-26.71M-23.95M-14.87M-10.53M
Net Income-43.89M-36.12M-26.73M-23.96M-14.84M-10.46M
Balance Sheet
Total Assets36.54M68.49M98.13M16.06M37.97M51.31M
Cash, Cash Equivalents and Short-Term Investments34.41M66.00M94.43M14.45M35.50M49.64M
Total Debt206.52K112.06K219.38K055.08K0
Total Liabilities5.53M8.02M2.86M4.19M3.21M3.03M
Stockholders Equity31.01M60.47M95.27M11.87M34.76M48.27M
Cash Flow
Free Cash Flow-34.03M-26.42M-29.31M-21.05M-14.09M-9.05M
Operating Cash Flow-33.97M-26.39M-14.56M-21.05M-13.55M-8.80M
Investing Cash Flow-8.56M-2.03M-14.76M0-536.84K-250.00K
Financing Cash Flow0-15.27K109.29M0-102.07K58.39M

Context Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.17

Price Trends

50DMA0.27Negative
100DMA0.40Negative
200DMA1.34Negative

Market Momentum

MACD-0.03Negative
RSI33.69Neutral
STOCH20.44Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.27, and below the 200-day MA of 1.34, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 33.69 is Neutral, neither overbought nor oversold. The STOCH value of 20.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTX.

Context Therapeutics Risk Analysis

Context Therapeutics disclosed 63 risk factors in its most recent earnings report. Context Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We may not be able to regain or maintain compliance with the continued listing standards of Nasdaq.Q3, 2026
2.There is substantial doubt regarding our ability to continue as a going concern. We will require additional capital to fund our operations, and if we are unable to obtain sufficient capital, we may need to curtail and reduce our operations and costs and modify our business strategy.Q3, 2026
3.There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.Q4, 2023

Context Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CNTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CNTXCNTX45Neutral$15.29M-0.36-96.54%――-66.49%
ADAGADAG40Underperform$122.20M-3.86-29.09%―8906.15%41.48%
WHWKWHWK40Underperform$184.70M-2.87-55.66%―-100.00%-825.52%
ANEBANEB33Underperform$11.42M-1.82-64.46%――33.15%

* Healthcare Sector Average

Performance Comparison

0%100%CNTXWHWKADAGANEBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CNTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CNTXContext Therapeutics, Inc.0.17-0.97-85.44%
WHWKWhitehawk Therapeutics, Inc.3.131.1457.29%
ADAGAdagene, Inc.1.820.052.82%
ANEBAnebulo Pharmaceuticals, Inc.0.28-2.01-87.77%

Context Therapeutics Corporate Events

Financial DisclosuresProduct-Related Announcements

Context Therapeutics Reports Q3 Results and CTIM-76 Trial Progress

Positive
Nov 10, 2026

On November 10, 2026, Context Therapeutics reported third-quarter results and pipeline updates. In its Phase 1 CTIM-76 trial, nine efficacy-evaluable platinum-resistant ovarian cancer patients receiving biologically active weekly doses had a 22% conf...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026